Overall survival from BC diagnosis was 47.69 ± 22.25 months (range 33-84, median 45.5 months); it was 52.25 ± 14.57 months (range 33-84, median 48.5 months) for the HR patients and 43.79 ± 27.14 months (range 9-101, median 39 months) for the RFA patients. Overall survival from BCLM treatment was 21.12 ± 12.78 months (range 9-64, median 15.5 months); in detail it was 29.42 ± 14.53 months (range 12-64, median 29.5 months) for the resected patients and 14 ± 4.45 months (range 9-24, median 13.5 months) for patients treated by RFA with a strongly significant survival difference for operated patients (p = 0.001). Overall disease-free survival from BCLM was 15.96 ± 13.16 months (range 3-64, median 12 months), disease-free survival for resected patients was 23.22 ± 16.2 months (range 8-64, median 18.5 months), and for patients treated by RFA was 9.64 ± 4.22 months (range 3-18, median 9 months; Fig. 1). Overall 1, 2, and 5 years (actuarial) survival was respectively 80.7, 57, and 31 %. Given in details for the two groups, they were respectively 100, 66.6 and 34 % (actuarial) for the resected group patients and 64.2, 21.4, and 11.5 % (actuarial) for the RFA patients. Fig. 1 Kaplan-Meier analysis of survival after BC and BCLM treatment. GROUP 1 = resection; GROUP 2 = RFA. Overall survival from breast cancer treatment (months) p = 0.082 ns. Overall survival from BCLM treatment (months) p = 0.001 CONCLUSIONS: Aggressive treatment on isolated BCLM may improve survival for these patients.

No abstract

No abstract

No abstract

No abstract